查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726374

全球抗凝血剂市场：市场规模、份额、趋势分析（按药物类别、给药途径、应用和地区）、细分市场预测（2025-2030 年）

Anticoagulants Market Size, Share & Trends Analysis Report By Drug Category (Novel Oral Anticoagulants, Direct Thrombin Inhibitors, Heparin), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 125 Pages | 商品交期: 2-10个工作天内

价格

抗凝血剂市场的成长与趋势：

根据Grand View Research, Inc.的最新报告，全球抗凝血剂市场规模预计到2030年将达到471亿美元，2025年至2030年期间的复合年增长率为4.8%。

市场发展的主要动力是心血管疾病（CVD）盛行率的上升和人口老化。根据世界卫生组织统计，2019年，心血管疾病是全球死亡的主要原因，造成1,790万人死亡，占全球死亡人数的32%。其中，85%是由于心臟病发作和中风引起的。此外，在1,700万因非传染性疾病而过早死亡的人口中，有38%是因心血管疾病而死亡。

此外，久坐的生活方式是导致全球因缺乏运动而血栓增加的主要原因，从而增加了对抗凝剂的需求。缺乏运动会增加静脉血栓栓塞症（VTE）的风险，包括肺动脉栓塞（PE）和深层静脉栓塞症（DVT）。当腿部深层静脉形成血栓时就会发生 DVT，而当血栓从深层静脉流向肺部时就会发生 PE。根据美国国家医学图书馆的数据，VTE（包括 DVT 和 PE）每年在美国影响约 90 万人。这次灾难导致数十万人住院，约30万人死亡。预计静脉血栓栓塞症 (VTE) 盛行率的上升和对有效治疗方案的需求的增加将推动市场的发展。

此外，它还透过促进技术创新、提高抗凝血治疗的有效性和安全性以及改善患者监测和结果，在振兴抗凝血剂市场方面发挥重要作用。药物发现和开发的进步已经产生了具有改良特性的新型抗凝血剂，例如半衰期更长、与其他药物的相互作用更少、出血风险更低。这些新型抗凝血剂为患者提供了更多的治疗选择和更好的治疗效果。根据美国国立卫生研究院介绍，基因疗法是一种治疗血栓的新方法，它利用基因来纠正导致血栓的潜在基因缺陷。儘管这种方法仍处于发展的早期阶段，但它有可能成为一种有效的血栓治疗方法。例如，2022年11月，FDA核准了基因治疗药物Hemgenix，用于使用预防性IX因子疗法治疗反覆出现严重出血事件的B型血友病成年患者。这是一种一次性基因疗法，将凝血因子 IX 的基因注入肝臟。

抗凝血剂市场报告重点

  • 根据药物类别，新型口服抗凝血剂 (NOAC) 部分将在全球抗凝血剂产业中占据主导地位，到 2024 年的收入份额将达到 57.2%。预计肝素部分在预测期内将大幅增加。
  • 2024 年，口服抗凝血剂占据全球抗凝血剂产业的最大收益占有率。根据给药途径，预计注射抗凝血剂领域将在 2025 年至 2030 年间实现成长。
  • 2024 年，心房颤动/心肌梗塞（心臟病发作）领域占据了全球抗凝血剂产业的主导地位。预计深层静脉栓塞症(DVT) 在预测期内将显着增长。
  • 到 2024 年，北美将在全球抗凝血剂产业占据主导地位，收入份额将达到 51.2%。预计在预测期内，亚太抗凝血剂市场将以 6.1% 的最快复合年增长率成长。

目录

第一章 分析方法与范围

第二章执行摘要

第三章抗凝血剂市场：驱动因素、趋势与范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 抗凝血剂市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章抗凝血剂市场：按药物类别的估计和趋势分析

  • 药品类别仪表板
  • 抗凝血剂市场：依药物类别进行差异分析
  • 全球抗凝血剂市场规模及趋势分析（依药物类别）（2018-2030）
  • 新型口服抗凝血药物（NOAC）
    • Elixir
    • 拜瑞妥
    • 萨瓦伊萨和利克西亚娜
    • 帕达克萨
  • 维生素K拮抗剂
  • 直接凝血酶抑制剂
  • 肝素
    • 种类
    • 原料

第五章抗凝血剂市场：依给药途径的估计与趋势分析

  • 给药途径仪表板
  • 抗凝血剂市场：按给药途径进行的变化分析
  • 全球抗凝血剂市场规模及给药途径趋势分析（2018-2030）
  • 口服抗凝血药
  • 注射用抗凝血剂

第六章抗凝血剂市场：按应用的估计和趋势分析

  • 用于特定目的的仪表板
  • 抗凝血剂市场：按应用进行差异分析
  • 全球抗凝血剂市场规模及应用趋势分析（2018-2030）
  • 心房颤动/心肌梗塞（心臟病发作）
  • 深层静脉栓塞症（DVT）
  • 肺动脉栓塞
  • 其他用途

第七章抗凝血剂市场：按地区估计和趋势分析

  • 市场仪表板：按地区
  • 各地区市场占有率分析（2024 年及 2030 年）
  • 抗凝血剂市场：按地区分類的要点
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争态势

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要企业热力图分析（2024年）
  • 公司简介
    • Aspen Holdings
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • GSK plc
    • Sanofi
    • Bayer AG
    • Boehringer Ingelheim International GmbH
    • DAIICHI SANKYO COMPANY, LIMITED
    • Johnson &Johnson Services, Inc.
    • Eisai Co., Ltd.
Product Code: GVR-4-68040-191-0

Anticoagulants Market Growth & Trends:

The global anticoagulants market size is expected to reach USD 47.10 billion by 2030, registering a CAGR of 4.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is primarily driven by the increasing prevalence of cardiovascular diseases (CVDs) and growing aging population. According to WHO, in 2019, CVDs caused majority of deaths worldwide, accounting for 17.9 million fatalities, which is 32% of global deaths. Among these deaths, 85% were attributed to heart attack and stroke. Moreover, of the 17 million premature deaths caused by noncommunicable diseases, 38% were due to CVDs in the same year.

Moreover, sedentary lifestyles significantly contribute to the global rise of blood clots owing to physical inactivity, fueling the demand for anticoagulants. Physical inactivity has been linked to an increased risk of venous thromboembolism (VTE), a condition that encompasses pulmonary embolism (PE) and deep vein thrombosis (DVT). The condition arises when a blood clot occurs in a deep vein in the legs, while PE occurs when a blood clot travels from a deep vein to the lungs. As per the National Library of Medicine, VTE, which includes DVT and PE, impacts around 900,000 individuals in the U.S. annually. This led to several hundred thousand hospitalizations and approximately 300,000 deaths. The increasing prevalence of VTE and the growing demand for effective treatment options is expected to boost the market.

Furthermore, technological advancements are playing a significant role in boosting the anticoagulants market by driving innovation, improving the efficacy and safety of anticoagulant treatments, and enhancing patient monitoring and outcomes. Advancements in drug discovery and development have led to the creation of new anticoagulants with improved properties, such as longer half-lives, fewer interactions with other medications, and reduced bleeding risks. These novel anticoagulants offer patients more treatment options and better outcomes. According to NIH, gene therapy is a new approach for treatment of blood clots that involves the use of genes to correct the underlying genetic defect that causes clotting. This approach is still in its early stage of development but has potential to be an effective treatment for blood clots. For instance, in November 2022, the FDA approved Hemgenix, a gene therapy to treat adults with hemophilia B who are using Factor IX prophylaxis and have a history of repeated, serious bleeding episodes. It is a one-time gene therapy that delivers a gene for clotting factor IX to the liver.

Anticoagulants Market Report Highlights:

  • Based on the drug category, the Novel Oral Anticoagulants (NOACs) segment dominated the global anticoagulants industry with a revenue share of 57.2% in 2024. Heparin segment is projected to experience significant growth over the forecast period.
  • Oral anticoagulants held the largest revenue share of the global anticoagulants industry in 2024. Based on route of administration, the injectable anticoagulants segment is anticipated to experience growth from 2025 to 2030.
  • The Atrial Fibrillation/Myocardial Infarction (Heart Attack) segment dominated the global anticoagulants industry in 2024. Deep Vein Thrombosis (DVT) is anticipated to experience significant growth over the forecast period.
  • North America dominated the global anticoagulants industry with revenue share of 51.2% in 2024. Asia Pacific anticoagulants market is anticipated to grow at the fastest CAGR of 6.1% during the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug category
    • 1.2.2. Route of administration
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Drug category outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Application outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anticoagulants Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Anticoagulants Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis

Chapter 4. Anticoagulants Market: Drug Category Estimates & Trend Analysis

  • 4.1. Drug Category Segment Dashboard
  • 4.2. Anticoagulants Market: Drug Category Movement Analysis
  • 4.3. Global Anticoagulants Market Size & Trend Analysis, by Drug Category, 2018 to 2030 (USD Million)
  • 4.4. Novel Oral Anticoagulants (NOACs)
    • 4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. Eliquis
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.3. Xarelto
      • 4.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4. Savaysa & lixiana
      • 4.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5. Pradaxa
      • 4.4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Vitamin K Antagonist
    • 4.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Direct Thrombin Inhibitors
    • 4.6.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Heparin
    • 4.7.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.2. Type
      • 4.7.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.2.2. Low Molecular Weight Heparin
        • 4.7.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.2.3. Ultra-low Molecular Weight Heparin
        • 4.7.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.2.4. Unfractionated Heparin
        • 4.7.2.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.7.3. Source
      • 4.7.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.3.2. Porcine
        • 4.7.3.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.3.3. Bovine
        • 4.7.3.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.7.3.4. Others
        • 4.7.3.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Anticoagulants Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Route of Administration Segment Dashboard
  • 5.2. Anticoagulants Market: Route of Administration Movement Analysis
  • 5.3. Global Anticoagulants Market Size & Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 5.4. Oral Anticoagulants
    • 5.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Injectable Anticoagulants
    • 5.5.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Anticoagulants Market: Application Estimates & Trend Analysis

  • 6.1. Application Segment Dashboard
  • 6.2. Anticoagulants Market: Application Movement Analysis
  • 6.3. Global Anticoagulants Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 6.4. Atrial Fibrillation/Myocardial Infarction (Heart Attack)
    • 6.4.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.5. Deep Vein Thrombosis (DVT)
    • 6.5.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.6. Pulmonary Embolism
    • 6.6.1. Market estimates and forecasts 2018 to 2030 (USD million)
  • 6.7. Other Applications
    • 6.7.1. Market estimates and forecasts 2018 to 2030 (USD million)

Chapter 7. Anticoagulants Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Dashboard
  • 7.2. Regional Market Share Analysis, 2024 & 2030
  • 7.3. Continuous bioprocessing market by Region: Key Takeaways
  • 7.4. North America
    • 7.4.1. U.S.
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Canada
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. Mexico
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. UK
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Germany
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. France
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Italy
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Spain
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. China
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.3. India
      • 7.6.3.1. Key country dynamics
      • 7.6.3.2. Regulatory framework/ reimbursement structure
      • 7.6.3.3. Competitive scenario
      • 7.6.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.4. Australia
      • 7.6.4.1. Key country dynamics
      • 7.6.4.2. Regulatory framework/ reimbursement structure
      • 7.6.4.3. Competitive scenario
      • 7.6.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key country dynamics
      • 7.6.5.2. Regulatory framework/ reimbursement structure
      • 7.6.5.3. Competitive scenario
      • 7.6.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Brazil
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Argentina
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. South Africa
      • 7.8.1.1. Key country dynamics
      • 7.8.1.2. Regulatory framework/ reimbursement structure
      • 7.8.1.3. Competitive scenario
      • 7.8.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.2. Saudi Arabia
      • 7.8.2.1. Key country dynamics
      • 7.8.2.2. Regulatory framework/ reimbursement structure
      • 7.8.2.3. Competitive scenario
      • 7.8.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key country dynamics
      • 7.8.3.2. Regulatory framework/ reimbursement structure
      • 7.8.3.3. Competitive scenario
      • 7.8.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.8.4. Kuwait
      • 7.8.4.1. Key country dynamics
      • 7.8.4.2. Regulatory framework/ reimbursement structure
      • 7.8.4.3. Competitive scenario
      • 7.8.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. Key company heat map analysis, 2024
  • 8.4. Company Profiles
    • 8.4.1. Aspen Holdings
      • 8.4.1.1. Company overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Pfizer Inc.
      • 8.4.2.1. Company overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Bristol-Myers Squibb Company
      • 8.4.3.1. Company overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. GSK plc
      • 8.4.4.1. Company overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Sanofi
      • 8.4.5.1. Company overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Bayer AG
      • 8.4.6.1. Company overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Boehringer Ingelheim International GmbH
      • 8.4.7.1. Company overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. DAIICHI SANKYO COMPANY, LIMITED
      • 8.4.8.1. Company overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. Johnson & Johnson Services, Inc.
      • 8.4.9.1. Company overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Eisai Co., Ltd.
      • 8.4.10.1. Company overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 Global anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 3 Global anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 4 Global anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 Global anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 6 North America anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 7 North America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 8 North America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 9 North America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 10 U.S. anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 11 U.S. anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12 U.S. anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 13 Canada anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 14 Canada anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 15 Canada anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 16 Mexico anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 17 Mexico anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Mexico anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 19 Europe anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 20 Europe anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 21 Europe anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 22 Europe anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 23 Germany anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 24 Germany anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 25 Germany anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 26 UK anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 27 UK anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 28 UK anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 29 France anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 30 France anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 31 France anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 32 Italy anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 33 Italy anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 34 Italy anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 35 Spain anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 36 Spain anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37 Spain anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 38 Asia Pacific anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 42 China anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 43 China anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 44 China anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 45 Japan anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 46 Japan anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 47 Japan anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 48 India anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 49 India anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 50 India anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 51 South Korea anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 52 South Korea anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53 South Korea anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 54 Australia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 55 Australia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 56 Australia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 57 Latin America anticoagulants market, by country, 2018 - 2030 (USD Million)
  • Table 58 Latin America anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 59 Latin America anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 60 Latin America anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 61 Brazil anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 62 Brazil anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 63 Brazil surgical anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 64 Argentina anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 65 Argentina anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66 Argentina surgical anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 67 MEA anticoagulants market, by region, 2018 - 2030 (USD Million)
  • Table 68 MEA anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 69 MEA anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70 MEA anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 71 South Africa anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 72 South Africa anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 73 South Africa anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 74 Saudi Arabia anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 75 Saudi Arabia anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 76 Saudi Arabia anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 77 UAE anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 78 UAE anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 79 UAE anticoagulants market, by application, 2018 - 2030 (USD Million)
  • Table 80 Kuwait anticoagulants market, by drug category, 2018 - 2030 (USD Million)
  • Table 81 Kuwait anticoagulants market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82 Kuwait anticoagulants market, by application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Anticoagulants market: market outlook
  • Fig. 10 Anticoagulants competitive insights
  • Fig. 11 Parent market outlook
  • Fig. 12 Related/ancillary market outlook
  • Fig. 13 Penetration and growth prospect mapping
  • Fig. 14 Industry value chain analysis
  • Fig. 15 Anticoagulants market driver impact
  • Fig. 16 Anticoagulants market restraint impact
  • Fig. 17 Anticoagulants market strategic initiatives analysis
  • Fig. 18 Anticoagulants market: Drug category movement analysis
  • Fig. 19 Anticoagulants market: Drug category outlook and key takeaways
  • Fig. 20 Novel Oral Anticoagulants (NOACs) market estimates and forecast, 2018 - 2030
  • Fig. 21 Eliquis market estimates and forecast, 2018 - 2030
  • Fig. 22 Xarelto market estimates and forecast, 2018 - 2030
  • Fig. 23 Savaysa & lixiana market estimates and forecast, 2018 - 2030
  • Fig. 24 Pradaxa market estimates and forecast, 2018 - 2030
  • Fig. 25 Vitamin K Antagonist market estimates and forecast, 2018 - 2030
  • Fig. 26 Direct Thrombin Inhibitors market estimates and forecast, 2018 - 2030
  • Fig. 27 Heparin market estimates and forecast, 2018 - 2030
  • Fig. 28 Low molecular weight heparin market estimates and forecast, 2018 - 2030
  • Fig. 29 Ultra-low molecular weight heparin market estimates and forecast, 2018 - 2030
  • Fig. 30 Unrationed heparin market estimates and forecast, 2018 - 2030
  • Fig. 31 Heparin sources market estimates and forecast, 2018 - 2030
  • Fig. 32 Porcine-based heparin market estimates and forecast, 2018 - 2030
  • Fig. 33 Bovine-based heparin market estimates and forecast, 2018 - 2030
  • Fig. 34 Other heparin market estimates and forecast, 2018 - 2030
  • Fig. 35 Others market estimates and forecast, 2018 - 2030
  • Fig. 36 Anticoagulants Market: Route of administration movement Analysis
  • Fig. 37 Anticoagulants market: Route of administration outlook and key takeaways
  • Fig. 38 Oral anticoagulants market estimates and forecasts, 2018 - 2030
  • Fig. 39 Injectable anticoagulants market estimates and forecasts,2018 - 2030
  • Fig. 40 Anticoagulants market: Application movement analysis
  • Fig. 41 Anticoagulants market: Application outlook and key takeaways
  • Fig. 42 Atrial Fibrillation/Myocardial Infarction (heart attack) market estimates and forecasts, 2018 - 2030
  • Fig. 43 Deep Vein Thrombosis (DVT) market estimates and forecasts,2018 - 2030
  • Fig. 44 Pulmonary embolism market estimates and forecasts, 2018 - 2030
  • Fig. 45 Other applications market estimates and forecasts,2018 - 2030
  • Fig. 46 Global anticoagulants market: Regional movement analysis
  • Fig. 47 Global anticoagulants market: Regional outlook and key takeaways
  • Fig. 48 North America market estimates and forecasts, 2018 - 2030
  • Fig. 49 U.S. market estimates and forecasts, 2018 - 2030
  • Fig. 50 Canada market estimates and forecasts, 2018 - 2030
  • Fig. 51 Mexico market estimates and forecasts, 2018 - 2030
  • Fig. 52 Europe market estimates and forecasts, 2018 - 2030
  • Fig. 53 UK market estimates and forecasts, 2018 - 2030
  • Fig. 54 Germany market estimates and forecasts, 2018 - 2030
  • Fig. 55 France market estimates and forecasts, 2018 - 2030
  • Fig. 56 Italy market estimates and forecasts, 2018 - 2030
  • Fig. 57 Spain market estimates and forecasts, 2018 - 2030
  • Fig. 58 Asia Pacific market estimates and forecasts, 2018 - 2030
  • Fig. 59 China market estimates and forecasts, 2018 - 2030
  • Fig. 60 Japan market estimates and forecasts, 2018 - 2030
  • Fig. 61 India market estimates and forecasts, 2018 - 2030
  • Fig. 62 South Korea market estimates and forecasts, 2018 - 2030
  • Fig. 63 Australia market estimates and forecasts, 2018 - 2030
  • Fig. 64 Latin America market estimates and forecasts, 2018 - 2030
  • Fig. 65 Brazil market estimates and forecasts, 2018 - 2030
  • Fig. 66 Argentina market estimates and forecasts, 2018 - 2030
  • Fig. 67 Middle East and Africa market estimates and forecasts, 2018 - 2030
  • Fig. 68 South Africa market estimates and forecasts, 2018 - 2030
  • Fig. 69 Saudi Arabia market estimates and forecasts, 2018 - 2030
  • Fig. 70 UAE market estimates and forecasts, 2018 - 2030
  • Fig. 71 Kuwait market estimates and forecasts, 2018 - 2030